Drospirenone

Drospirenone

Clinical data
Pregnancy category	US: X (Contraindicated)
Routes of administration	Oral
ATC code	G03AA12 (WHO)
Pharmacokinetic data
Bioavailability	76%
Protein binding	97%
Metabolism	Hepatic, minor (CYP3A4-mediated)
Elimination half-life	30 hours
Excretion	Renal and fecal
Identifiers
IUPAC name (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)- 1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16- hexadecahydro-10,13-dimethylspiro- [17H-dicyclopropa-6,7:15,16]cyclopenta [a]phenanthrene-17,2'(5H)-furan]-3,5'(2H)-dione)
CAS Number	67392-87-4
PubChem CID	68873
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C24H30O3
Molar mass	366.493 g/mol

WikiDoc Resources for Drospirenone
Articles
Most recent articles on Drospirenone Most cited articles on Drospirenone Review articles on Drospirenone Articles on Drospirenone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Drospirenone Images of Drospirenone Photos of Drospirenone Podcasts & MP3s on Drospirenone Videos on Drospirenone
Evidence Based Medicine
Cochrane Collaboration on Drospirenone Bandolier on Drospirenone TRIP on Drospirenone
Clinical Trials
Ongoing Trials on Drospirenone at Clinical Trials.gov Trial results on Drospirenone Clinical Trials on Drospirenone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Drospirenone NICE Guidance on Drospirenone NHS PRODIGY Guidance FDA on Drospirenone CDC on Drospirenone
Books
Books on Drospirenone
News
Drospirenone in the news Be alerted to news on Drospirenone News trends on Drospirenone
Commentary
Blogs on Drospirenone
Definitions
Definitions of Drospirenone
Patient Resources / Community
Patient resources on Drospirenone Discussion groups on Drospirenone Patient Handouts on Drospirenone Directions to Hospitals Treating Drospirenone Risk calculators and risk factors for Drospirenone
Healthcare Provider Resources
Symptoms of Drospirenone Causes & Risk Factors for Drospirenone Diagnostic studies for Drospirenone Treatment of Drospirenone
Continuing Medical Education (CME)
CME Programs on Drospirenone
International
Drospirenone en Espanol Drospirenone en Francais
Business
Drospirenone in the Marketplace Patents on Drospirenone
Experimental / Informatics
List of terms related to Drospirenone

Drospirenone is a synthetic progestin that is an analog to spironolactone. Its molecular weight is 366.5 and its molecular formula is C₂₄H₃₀O₃.

Properties and uses

The compound is part of certain birth control formulations. Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic. With its activities similar to spironolactone it may lead to less water retention and breast tenderness and improved skin appearance (less acne).

Drospirenone is taken orally with about 76% bioavailability. It is not bound by sex hormone binding globulin or corticosteroid binding globulin, but by other serum proteins. Metabolites have not been shown to be biologically active, show up in urine and feces, and are essentially completely excreted within 10 days.

The compound is part of certain newer oral contraceptive formulations:

• Yasmin® contains 3 mg drospirenone and 30 mcg ethinylestradiol per tablet. It is indicated for the prevention of pregnancy in women who elect an oral contraceptive.
• Yaz® contains 3 mg drospirenone and 20 mcg ethinylestradiol per tablet and is given for 24/4 days with the same indications.

It has also been formulated in medication to manage menopausal symptoms using 0.5 mg drsp and 1 mg estradiol per day by oral application. This medication was introduced in the USA in 2007 as Angeliq®.

Drospirenone, which can potentially cause hyperkalemia in high-risk patients, is comparable to a 25mg dose of spironolactone.

The medication is contraindicated in patients with hepatic dysfunction, renal insufficiency, adrenal insufficiency, or in whom the use of oral contraceptives is contraindicated, such as smokers and patients with a history of DVT, stroke, or other blood clots. Because of the anti-mineralocorticoid effects care needs to be exercised when other drugs that may increase potassium levels are taken. Such medications include ACE inhibitors, angiotensin-II receptor agonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDs.

See also

• Progestins
• Combined oral contraceptive pill
• Oral contraceptive formulations
• Hormone replacement therapy

References

• Krattenmacher R (2000). "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen". Contraception. 62 (1): 29–38. PMID 11024226.
• Yasmin product information
• Angeliq product information

External links

• Medline information
• Yasmin Survivors Forum